WallStSmart

BeyondSpring Inc (BYSI)vsModerna Inc (MRNA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 134495% more annual revenue ($2.52B vs $1.88M). BYSI leads profitability with a 0.0% profit margin vs -110.5%. MRNA earns a higher WallStSmart Score of 31/100 (F).

BYSI

Avoid

20

out of 100

Grade: F

Growth: 5.0Profit: 3.0Value: 6.7Quality: 4.5
Piotroski: 2/9Altman Z: -22.81

MRNA

Avoid

31

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BYSIUndervalued (+89.1%)

Margin of Safety

+89.1%

Fair Value

$13.03

Current Price

$0.33

$12.70 discount

UndervaluedFair: $13.03Overvalued
MRNAUndervalued (+73.2%)

Margin of Safety

+73.2%

Fair Value

$150.95

Current Price

$195.00

$44.05 discount

UndervaluedFair: $150.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BYSI1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.0010/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 8.5/10
Market CapQuality
$101.49B9/10

Large-cap with strong market position

Revenue GrowthGrowth
29.2%8/10

Revenue surging 29.2% year-over-year

Areas to Watch

BYSI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$26.47M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

MRNA4 concerns · Avg: 2.8/10
Price/BookValuation
11.5x4/10

Trading at 11.5x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-40.8%2/10

ROE of -40.8% — below average capital efficiency

EPS GrowthGrowth
-85.1%2/10

Earnings declined 85.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : BYSI

The strongest argument for BYSI centers on Debt/Equity. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.

Bear Case : BYSI

The primary concerns for BYSI are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

BYSI profiles as a value stock while MRNA is a growth play — different risk/reward profiles.

MRNA carries more volatility with a beta of 1.17 — expect wider price swings.

MRNA is growing revenue faster at 29.2% — sustainability is the question.

BYSI generates stronger free cash flow (-4M), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (31/100 vs 20/100) and 29.2% revenue growth. BYSI offers better value entry with a 89.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BeyondSpring Inc

HEALTHCARE · BIOTECHNOLOGY · USA

BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?